Skip to main content

Table 2 Characteristics of HIV infected pregnant women, USA versus Europe: disease progression and treatment

From: Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA

Characteristic USA Europe Overall P-value
Median CD4 count: entry (IQR) 437 (293–600) 420 (299–568) 430 (294–592) 0.6958
<200 cells per ml 124 (13%) 37 (10%) 161 (12%)  
200–499 294 (30%) 132 (35%) 426 (32%)  
≥500 560 (57%) 203 (55%) 763 (57%)  
Median HIV RNA: entry (IQR) 581 (274–3635) 700 (200–4740) 594 (243–3845) 0.1225
≤400 copies/ml 424 (43%) 142 (38%) 566 (42%)  
400–2,499 252 (26%) 92 (24%) 344 (25%)  
2,500–10,000 143 (15%) 62 (17%) 205 (15%)  
>10,000 138 (14%) 57 (15%) 195 (14%)  
Median CD4 count: delivery (IQR) 480 (308–658) 444 (320–632) 469 (310–653) 0.6849
<200 cells/ml 103 (12%) 26 (8%) 129 (11%)  
200–499 233 (27%) 109 (34%) 342 (29%)  
≥500 531 (61%) 187 (58%) 718 (60%)  
Median HIV RNA: delivery (IQR) 405 (237–2638) 200 (68–1300) 400 (200–2300) 0.0001
≤400 copies/ml 450 (50%) 176 (64%) 626 (53%)  
400–2,499 220 (24%) 49 (18%) 269 (23%)  
2,500–10,000 115 (13%) 36 (14%) 151 (13%)  
>10,000 116 (13%) 16 (6%) 132 (11%)  
Maternal ARV use     <0.0001
HAART 448 (46%) 119 (32%) 567 (42%)  
Dual therapy 342 (35%) 132 (35%) 474 (35%)  
Monotherapy 182 (19%) 119 (32%) 301 (22%)  
No ARV 6 (0.6%) 2 (0.5%) 8 (0.6%)  
Timing of ARV initiation     0.0001
Pre-pregnancy 357 (37%) 182 (49%) 539 (40%)  
During pregnancy 606 (63%) 190 (51%) 796 (60%)  
Symptomatic HIV disease at entry     0.0194
Yes 74 (8%) 15 (4%) 89 (7%)  
No 904 (92%) 357 (96%) 1261 (93%)